IFRX - InflaRx N.V. News

Discover

IFRX

InflaRx N.V.

2.00

19 x 2.00

8 x 2.01

bid

ask

0.04

2.26%

01:33 PM

timesize

Ytd	98.44%
1y	143.52%

1.92

day range

2.02

0.78

52 week range

2.95

Open	1.99	Prev Close	1.96	Low	1.92	High	2.02	Mkt Cap	295.20M
Vol	227.94K	Avg Vol	1.23M	EPS	-0.53	P/E	-3.78	Forward P/E	-2.36
Beta	2.48	Short Ratio	5.17	Inst. Own	22.52%	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	08-06	50-d Avg	1.90	200-d Avg	1.43	1yr Est	8.09

IFRX News

globenewswire.com

InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones

Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; cli

globenewswire.com

InflaRx to Report Second Quarter 2026 Results on August 6, 2026

Jena, Germany, July 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical c

defenseworld.net

Reviewing InflaRx (NASDAQ:IFRX) and Kamada (NASDAQ:KMDA)

Kamada (NASDAQ: KMDA - Get Free Report) and InflaRx (NASDAQ: IFRX - Get Free Report) are both small-

globenewswire.com

InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Followi

Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical c

seekingalpha.com

InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal D

benzinga.com

12 Health Care Stocks Moving In Friday's After-Market Session

marketbeat.com

InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline

InflaRx NASDAQ: IFRX outlined plans to prioritize development of izicopan, an oral inhibitor of the

globenewswire.com

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares

Jena, Germany, May 08, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biop

benzinga.com

12 Health Care Stocks Moving In Wednesday's Intraday Session

globenewswire.com

InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares

Jena, Germany, May 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a bioph

globenewswire.com

InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases

Jena, Germany, May 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical co

globenewswire.com

InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes

JENA, Germany, May 04, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical com

globenewswire.com

InflaRx to Report First Quarter 2026 Results on May 7, 2026

JENA, Germany, May 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical com

benzinga.com

12 Health Care Stocks Moving In Tuesday's Intraday Session

globenewswire.com

InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

JENA, Germany, April 28, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical c

benzinga.com

10 Health Care Stocks Moving In Friday's Intraday Session

globenewswire.com

InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR I

JENA, Germany, April 09, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical c

globenewswire.com

InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium

JENA, Germany, March 31, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical c

globenewswire.com

InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Pre

Jena, Germany, March 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical

defenseworld.net

InflaRx N.V. (NASDAQ:IFRX) Receives $6.17 Consensus PT from Analysts

InflaRx N.V. (NASDAQ: IFRX - Get Free Report) has been assigned a consensus recommendation of "Moder

defenseworld.net

Reviewing Athira Pharma (NASDAQ:ATHA) & InflaRx (NASDAQ:IFRX)

InflaRx (NASDAQ: IFRX - Get Free Report) and Athira Pharma (NASDAQ: ATHA - Get Free Report) are both

zacks.com

InflaRx N.V. (IFRX) Reports Q4 Loss, Lags Revenue Estimates

InflaRx N.V. (IFRX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Est

globenewswire.com

InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones

Promising Phase 2a data announced for izicopan, underscoring its potential as a meaningfully differe

benzinga.com

Earnings Scheduled For March 19, 2026

globenewswire.com

InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangreno

JENA, Germany, March 18, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical c

benzinga.com

12 Health Care Stocks Moving In Friday's Pre-Market Session

benzinga.com

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

benzinga.com

12 Health Care Stocks Moving In Monday's Intraday Session

benzinga.com

12 Health Care Stocks Moving In Monday's Pre-Market Session

benzinga.com

Earnings Scheduled For August 7, 2025

benzinga.com

US Stocks Gain; Abercrombie & Fitch Posts Upbeat Earnings

benzinga.com

Why Box Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket

benzinga.com

Earnings Scheduled For May 7, 2025

benzinga.com

Carnival Surges Over 12%, Here's 75 Biggest Movers From Friday

Gainers USA Truck, Inc. (NASDAQ: USAK) shares climbed 112.6% to close at $31.00 on Friday. DB Sc

benzinga.com

Stocks That Hit 52-Week Lows On Wednesday

On Wednesday, 215 companies set new 52-week lows.

benzinga.com

Stocks That Hit 52-Week Lows On Tuesday

On Tuesday, 540 companies set new 52-week lows.

benzinga.com

Stocks That Hit 52-Week Lows On Friday

On Friday, 1043 companies hit new 52-week lows.

benzinga.com

Stocks That Hit 52-Week Lows On Wednesday

During Wednesday's trading, 435 companies set new 52-week lows.